Achilles Therapeutics Plc – ADR (NASDAQ: ACHL) shares gained 1.97%, or $0.14 per share, to close Wednesday at $7.24. After opening the day at $7.10, shares of Achilles fluctuated between $7.53 and $6.93. 308,494 shares traded hands a decrease from their 30 day average of 401,730. Wednesday’s activity brought Achilles’s market cap to $293,969,260.
Achilles is headquartered in 245 Hammersmith Road, London..
About Achilles Therapeutics Plc – ADR
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Visit Achilles Therapeutics Plc – ADR’s profile for more information.
The Daily Fix
Here’s a trending selection from our newsletter, The Daily Fix, that captured readers’ attention. Click here to subscribe and get The Daily Fix delivered right to your inbox.
How Entrepreneurs Can Build and Maintain Successful Venture Capital and Private Equity Relationships
The first three quarters of 2021 have brought ample opportunity for startups and small businesses seeking capital investments. According to a report from PitchBook, overall venture capital funding in the U.S. hit a new record of $238.7 billion raised in the first nine months of the year, crushing the previous annual record of $166.4 billion that was raised in all of 2020. Early-stage capital alone has exceeded $54 billion through Sept. 30, beating last year’s record volume of $44 billion.
With more opportunity, however, comes more competition. Entrepreneurs who have decided to seek venture capital or private equity investment will need to stand out. Strategizing around getting and keeping investor attention early on can help.
McDonald’s To Offer New Plant-Based Burger in US Restaurants by Beyond Meat
McDonald’s Corporation (NYSE: MCD) will soon launch a small-scale rollout in the US of a new plant-based burger developed with faux-meat maker Beyond Meat Inc (Nasdaq: BYND).
Starting Nov. 3, the “McPlant” will be on the menu at eight locations in Texas, Louisiana, Iowa and California as part of a trial run to help gauge customer interest in the meatless offering, McDonald’s announced last week.
Keep Your Friends Close, But Your Enemies Closer — Part I
Revenge represents an amazing human activity. In business, kicking opponents when they are down comes with the territory. As Huawei struggles with US government sanctions, Xiaomi steps in to introduce competing products and grab market share. Former Communists learn quickly about the free market economy. No employee at Facebook (NASDAQ: FB) asks the giant to go easy on Myspace. Remember Myspace? No Apple (NASDAQ: AAPL) executive lends a helping hand to Motorola, which is even harder to remember. This new series looks at a few savory examples of business payback.
About The Nasdaq Stock Market
The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world’s leading exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.
To get more information on Achilles Therapeutics Plc – ADR and to follow the company’s latest updates, you can visit the company’s profile page here: Achilles Therapeutics Plc – ADR’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: www.equities.com/disclaimer
Read more here: Source link